SAN ANTONIO — Weekly patient-reported outcomes monitoring combined with an automated alert system improved fatigue and overall quality of life and prolonged survival in patients with […]

New biomarker analyses from the phase 3 KEYNOTE-522 trial provide insights into the biological factors that may influence response to pembrolizumab plus chemotherapy in early-stage triple-negative […]

SAN ANTONIO — Patients with early-stage, node-negative, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and a high risk for recurrence benefited […]

SAN ANTONIO — Women 70 years or older with early luminal A-like breast cancer who received postoperative radiotherapy alone following surgery reported having better health-related quality […]

Chimeric antigen receptor (CAR)-T cells and T-cell therapies have been used in the treatment of various cancers for several years. In a review published in JAMA, […]

SAN DIEGO — The multiple myeloma (MM) drug daratumumab (Darzalex), an anti-CD38 monoclonal antibody, dramatically reduced progression to active MM or death in patients with high-risk […]

The phase 3 PADMA trial demonstrated that first-line treatment with palbociclib plus endocrine therapy (ET) significantly improves outcomes compared with standard mono chemotherapy in patients with […]